mRNA-4157,Pembrolizumab
merck,moderna
['melanoma', 'pembro']
presented at #aacr23: adjuvant therapy w/ personalized vaccine and pembrolizumab vs pembrolizumab alone showed benefits in time to recurrence in high risk resected melanoma. phase 3 trial plans are underway in patients with melanoma. 
The Melanoma Research Foundation (MRF) is the largest independent organization devoted to #melanoma. Help us find pathways to a cure! #GetNaked